Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–88 of 88 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperpigmentation Clear all

Conditions: Burn Scar, Hypertrophic Scar, Hyperpigmentation, Hypopigmented Scar
Interventions: Not listed
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Photodamage
Interventions: Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .; Device
Lead sponsor: Alma Lasers Inc.; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Edina, Minnesota

Conditions: Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions: oCRH; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 70 Years
Enrollment: 1,387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melasma
Interventions: Radiofrequency microneedling; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Facial Hyperpigmentation
Interventions: Test cosmetic product; Drug
Lead sponsor: Kayuraeffect, LLP; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Miami Lakes, Florida • New York, New York

Conditions: Periorbital Hyperpigmentation, Periorbital Edema, Fine Lines, Wrinkle
Interventions: Gentle Cleansing Lotion, Facial Moisturizer, Sunscreen SPF 30; Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Acne Vulgaris, Post Inflammatory Hyperpigmentation
Interventions: Azelaic acid; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Melasma
Interventions: Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Los Angeles, California • Dallas, Texas

Conditions: Headache, Cognitive Disturbance, Skin Hyperpigmentation, Arthralgia
Interventions: Calcium DTPA, Zinc DTPA; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2065
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acanthosis Nigricans
Interventions: Sirolimus 0.2%; Drug
Lead sponsor: Narrows Institute for Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Acne, Post Inflammatory Hyperpigmentation
Interventions: Liftactiv B3, Sunscreen; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Actinic Keratosis
Interventions: AKRQ questionnaire, Skindex-16, DLQI, Skin Health Calculator; Other
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Melasma
Interventions: DOSE formulation; Other
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Acne Vulgaris, Post Inflammatory Hyperpigmentation, Post Inflammatory Pigmentation Change, Erythema, Skin Scarring
Interventions: Tazarotene 0.045% Lotion; Drug
Lead sponsor: Dr. Emmy Graber; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melasma
Interventions: Polypodium Leucotomos, Placebo; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Characterization of Dyschromic Hypertrophic Scar

Laser 360iQ: Optimal Light-laser Combination Therapy

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Efficacy of Radiofrequency Micro Needling for the Treatment of Melasma in Skin of Color.

Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation

A 12 Week Study to Evaluate the Efficacy of an Eye Cream

Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

RASopathy Biorepository

Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

Development and Validation of a Quality of Life Instrument for Actinic Keratosis

Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

Oral Polypodium Leucotomos for Melasma